Cite
HARVARD Citation
Higgins, J. et al. (2022). A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease. Journal of clinical rheumatology. 28 (7), pp. 338-345. [Online].